Pear Therapeutics (Nasdaq:PEAR) announced positive data supporting its reSET prescription digital therapeutic (PDT).
Boston-based Pear designed FDA-authorized reSET for the treatment of substance use disorder (SUD). That includes alcohol, cannabis, cocaine, and stimulants like methamphetamines.
The real-world study demonstrated high rates of engagement, retention and abstinence from substances with reSET through 12 weeks. The American Journal on Addictions (AJA) published the data.
reSET provides cognitive behavioral therapy as an adjunct to a contingency management system. Its indication covers patients aged 18 years and older currently enrolled in outpatient treatment under clinician supervision. The 12-week (90-day) prescription-only treatment covers SUD patients not currently on opioid replacement therapy. Those patients do not abuse alcohol solely. They also do not abuse opioids as their primary substance of abuse.
The data from Pear Therapeutics’ study
The real-world observational analysis covered an all-comer population of 602 patients. It evaluated substance use as a composite of self-reports and urine screens.
More than 74% of patients remained in reSET treatment and used their PDT during the final four weeks. Abstinence rates during that period totaled 62%. That analysis treated missing data as a positive urine screen. Meanwhile, abstinence came in at 86% where authors excluded missing data from the analysis.
Of patients using reSET appropriately, 81% presented abstinence and the study retained 92% at 12 weeks. That includes patients on four or more lessons per week on average in the first four weeks.
“Nearly half of people who begin a treatment program stop within the first three months, which makes it challenging to effectively treat patients throughout their entire recovery journey,” said Dr. Yuri Maricich, CMO, Pear Therapeutics. “The high rates of engagement and retention we observed in this analysis are especially encouraging as they demonstrate the potential benefit of reSET in treating patients in diverse and naturalistic real-world settings with substance use disorder, a population in need of effective therapies.”